J Treleaven

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial

R Powles, Jayesh Mehta, Samar Kulkarni et al. · The Lancet · 2000 · 355 citations

Transplantation, Marrow Transplantation, Medicine +12

HIGH-DOSE INTRAVENOUS IgG IN ADULTS WITH AUTOIMMUNE THROMBOCYTOPENIA

Adrian C. Newland, J Treleaven, R. M. Minchinton et al. · The Lancet · 1983 · 249 citations

Thrombopoiesis, Thrombosis, Autoimmune Disease +7

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold?

Seema Singhal, R Powles, J Treleaven et al. · Bone Marrow Transplantation · 2000 · 110 citations

Hematological Malignancy, Transplantation, Cd34+ Cells/kg +6

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

Seema Singhal, R Powles, Bhawna Sirohi et al. · Bone Marrow Transplantation · 2002 · 83 citations

Hematological Malignancy, Survival Benefit, Medicine +6

Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease

Fiona L. Dignan, Dorothy M. Gujral, Mark Ethell et al. · Bone Marrow Transplantation · 2007 · 81 citations

Transplantation, Marrow Transplantation, Prophylactic Defibrotide +9